Laser injury requires second opinion

Article

A 56 year-old male patient came into the clinic recently for a second opinion concerning a previous injury to his right eye. A high-powered commercial laser in a physics laboratory was the source of the injury in 2005.

Figure 1A

 

 

 


 

 

 

 

 

 

 

 

 

A 56 year-old male patient came into the clinic recently for a second opinion concerning a previous injury to his right eye. A high-powered commercial laser in a physics laboratory was the source of the injury in 2005. He is currently a full-time spectacle lens wearer. The medical history is significant for the following: appendectomy 1980; systemic hypertension treated and controlled with oral medications for the past 6-7 years; hyperlipidemia treated with Lipitor (atorvastatin calcium, Pfizer) for 3 years. He is a former smoker, but a pack-year calculation was not recorded. He reports no known allergies. Regarding his family history, he reports that his mother has been treated for liver cancer. 

Figure 1B

Pertinent clinical findings include:

• Visual acuity: OD 5/25 (EV), OS 20/20

• IOP: 20/21 mm Hg OD/OS

• The anterior segment was unremarkable, and visual field was full to confrontation testing.

• EOMs: no restrictions.

Figure 2

The figures show the fundus appearance of the right and left eyes (Figures 1 and 2). In addition, an OCT characterized carefully the architectural changes at the level of the outer and inner retina at the macula (Figures 3 and 4).

Because this represents stable retinal/RPE remodeling, no treatment was recommended. He will continue to be followed, recommended to wear safety glasses, and to observe laser safety protocols as recommended by manufacturers.ODT

Figure 3

Figure 4

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Dr. Julie Rodman previews her SECO presentations
© 2025 MJH Life Sciences

All rights reserved.